2010

06/30/10 - Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy

06/23/10 - Spherix Expands Development Strategy for D-Tagatose Seeks Pharma Partner For Continued Development in Diabetes

05/03/10 - Spherix to Present at 2010 BIO International Convention in Chicago

04/01/10 - Spherix Announces 2009 Financial Results

01/12/10 - Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes

01/11/10 - Spherix To Present at Annual Onemedplace Finance Forum and at EBD Biotech Showcase In San Francisco

2009

11/19/09 - Spherix Announces Results of Annual Shareholders Meeting

11/19/09 - Spherix Announces the Closing of $6.3 Million Registered Direct Offering

11/16/09 - Spherix Reports Third Quarter 2009 Earnings

11/16/09 - Spherix Incorporated to Raise $6.3 Million in Registered Direct Offering

11/16/09 - Spherix Announces Positive Interim Results In Phase 3 Trial of Novel, Oral Compound for Type 2 Diabetes

11/13/09 - Spherix Incorporated to Webcast Formal Remarks from Annual Meeting of Shareholders

09/23/09 - Spherix Incorporated Announces Annual Shareholders Meeting Date

09/10/09 – Spherix Incorporated Appoints Dr. Ram Nimmagudda as Director of New Business Development

09/03/09 – Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

08/17/09 – Spherix Reports Second Quarter 2009 Earnings

06/24/09 – Spherix Announces Positive Phase 2 Study Results

06/23/09 – Spherix Announces Termination of Arla License Agreement

06/23/09 – Spherix Announces Full-Scale Production of Pharmaceutical Tagatose

05/22/09 – Spherix Regains Full NASDAQ Compliance

05/14/09 – Spherix Reports First Quarter 2009 Earnings

05/14/09 – Spherix Elects New Independent Director, and Elects Chairman of the Board

05/14/09 – Spherix to Exhibit at the BIO International 2009 Convention

04/27/09 – Spherix Recruiting New “Independent” Director to Regain NASDAQ Compliance

04/17/09 – Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board

03/31/09 – Spherix Incorporated Holds 2008 Earnings Conference Call

03/30/09 – Spherix Announces 2008 Financial Results

03/11/09 – Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data

2008

11/19/08 – Spherix Stockholders Authorize Potential Reverse Stock Split

11/13/08 – Spherix Reports 3rd Quarter Earnings

11/10/08 – Spherix Transfers Stock Listing to NASDAQ Capital Market

11/07/08 – Patient Recruitment Begins in India for Phase 3 Diabetes Trial

10/23/08 – Spherix Receives NASDAQ Letter Extending Minimum Bid Price Compliance Person

09/08/08 – Spherix Incorporated to Seek Stockholder Approval of Reverse Stock Split

08/14/08 – Spherix Reports 2nd Quarter Earnings

07/23/08 – Spherix Receives NASDAQ Bid Price Deficiency Letter

07/14/08 – Spherix Expands Phase 3 Naturlose® Diabetes Trial Outside of the U.S.

05/14/08 – Spherix Reports 1st Quarter Earnings

05/14/08 – Spherix Holds Annual Shareholders Meeting

05/12/08 – Market Research Shows Spherix’s Naturlose® Readily Accepted by Diabetes Patients; Meets MD’s Treatment Need

04/30/08 – Spherix D-Tagatose to be Supplied by Inalco S.p.A.

04/17/08 – Spherix Hires Key Employees

04/03/08 – Spherix Reports 2007 Financial Results

2007

11/29/07 – Growth Achieved in Spherix’s Health Sciences Business

11/16/07 – Spherix Reports 3rd Quarter Earnings

08/16/07 – Spherix Shareholders Support Company’s Focus on Naturlose®, Biotechnology

08/14/07 – Spherix Reports Second Quarter Earnings

08/09/07 – Spherix Launches Health Sciences Consulting Business Line

06/27/07 – Spherix Signs Definitive Agreement for Sale of Information Subsidiary

05/14/07 – Spherix Reports 1st Quarter Earnings

05/01/07 – Spherix Announces Start of Phase 3 Clinical Trial

04/26/07 – Spherix Signs Letter of Intent for the Sale of its Information Subsidiary

03/30/07 – Spherix Reports Record 2006 Financial Results

02/22/07 – InfoSpherix Adds Golf Package to its ReserveWorld Business Line